Phase II Study of Niraparib and TSR-042 in Patients With Germline or Somatic BRCA1/2 and PALB2-Related Pancreatic Cancer
The purpose of this phase II study is to evaluate the safety and efficacy of niraparib and dostarlimab in patients with germline or somatic BRCA 1 or BRCA2 and PALB2 mutated metastatic pancreatic cancer.
Study ID: MC1841
Trial Phase: Phase II
Trial Sponsor: Mayo Clinic
Therapies Used in This Trial: Niraparib, Dostarlimab